WallStreetZenWallStreetZen

NASDAQ: GNLX
Genelux Corp Stock Forecast, Predictions & Price Target

Analyst price target for GNLX

Based on 2 analysts offering 12 month price targets for Genelux Corp.
Min Forecast
$25.00+920.41%
Avg Forecast
$28.50+1,063.27%
Max Forecast
$32.00+1,206.12%

Should I buy or sell GNLX stock?

Based on 2 analysts offering ratings for Genelux Corp.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their GNLX stock forecasts and price targets.

GNLX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-06-03
lockedlocked$00.00+00.00%2024-05-13

1 of 1

Forecast return on equity

Is GNLX forecast to generate an efficient return?
Company
-93.07%
Industry
72.03%
Market
80.59%
GNLX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GNLX forecast to generate an efficient return on assets?
Company
-56.89%
Industry
30.89%
GNLX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GNLX earnings per share forecast

What is GNLX's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$0.86
Avg 2 year Forecast
-$1.41
Avg 3 year Forecast
-$1.02

GNLX revenue forecast

What is GNLX's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$41.2M+514,900%
Avg 2 year Forecast
$86.5M+1,080,525%
Avg 3 year Forecast
$168.2M+2,101,775%
GNLX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GNLX revenue growth forecast

How is GNLX forecast to perform vs Biotechnology companies and vs the US market?
Company
2,630.96%
Industry
65.11%
Market
11.3%
GNLX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GNLX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GNLX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GNLX$2.45$28.50+1,063.27%Buy
GNTA$3.63$25.00+588.71%Buy
EYEN$1.23$12.00+875.61%Buy
INTS$4.84$12.00+147.93%Buy
VTVT$22.11N/AN/A

Genelux Stock Forecast FAQ

Is Genelux Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: GNLX) stock is to Buy GNLX stock.

Out of 2 analysts, 0 (0%) are recommending GNLX as a Strong Buy, 2 (100%) are recommending GNLX as a Buy, 0 (0%) are recommending GNLX as a Hold, 0 (0%) are recommending GNLX as a Sell, and 0 (0%) are recommending GNLX as a Strong Sell.

If you're new to stock investing, here's how to buy Genelux stock.

What is GNLX's earnings growth forecast for 2024-2026?

(NASDAQ: GNLX) Genelux's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.75%.

Genelux's earnings in 2024 is -$25,783,000.On average, 2 Wall Street analysts forecast GNLX's earnings for 2024 to be -$23,217,196, with the lowest GNLX earnings forecast at -$28,616,544, and the highest GNLX earnings forecast at -$17,817,848. On average, 1 Wall Street analyst forecast GNLX's earnings for 2025 to be -$38,065,403, with the lowest GNLX earnings forecast at -$38,065,403, and the highest GNLX earnings forecast at -$38,065,403.

In 2026, GNLX is forecast to generate -$27,536,675 in earnings, with the lowest earnings forecast at -$27,536,675 and the highest earnings forecast at -$27,536,675.

What is GNLX's revenue growth forecast for 2026-2028?

(NASDAQ: GNLX) Genelux's forecast annual revenue growth rate of 2,630.96% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.11%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.3%.

Genelux's revenue in 2024 is $8,000.On average, 1 Wall Street analysts forecast GNLX's revenue for 2026 to be $1,112,265,688, with the lowest GNLX revenue forecast at $1,112,265,688, and the highest GNLX revenue forecast at $1,112,265,688. On average, 2 Wall Street analysts forecast GNLX's revenue for 2027 to be $2,333,868,173, with the lowest GNLX revenue forecast at $1,889,771,800, and the highest GNLX revenue forecast at $2,777,964,546.

In 2028, GNLX is forecast to generate $4,539,501,831 in revenue, with the lowest revenue forecast at $3,779,543,600 and the highest revenue forecast at $5,299,460,062.

What is GNLX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: GNLX) forecast ROA is -56.89%, which is lower than the forecast US Biotechnology industry average of 30.89%.

What is GNLX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year GNLX price target, the average GNLX price target is $28.50, with the highest GNLX stock price forecast at $32.00 and the lowest GNLX stock price forecast at $25.00.

On average, Wall Street analysts predict that Genelux's share price could reach $28.50 by Jun 3, 2025. The average Genelux stock price prediction forecasts a potential upside of 1,063.27% from the current GNLX share price of $2.45.

What is GNLX's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: GNLX) Genelux's current Earnings Per Share (EPS) is -$0.97. On average, analysts forecast that GNLX's EPS will be -$0.86 for 2024, with the lowest EPS forecast at -$1.06, and the highest EPS forecast at -$0.66. On average, analysts forecast that GNLX's EPS will be -$1.41 for 2025, with the lowest EPS forecast at -$1.41, and the highest EPS forecast at -$1.41. In 2026, GNLX's EPS is forecast to hit -$1.02 (min: -$1.02, max: -$1.02).

What is GNLX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: GNLX) forecast ROE is -93.07%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.